Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients (CIRCULAR)

  • End date
    Jan 1, 2024
  • participants needed
  • sponsor
    Institut Bergonié
Updated on 24 March 2022
liquid biopsy
lung carcinoma


Multicenter prospective cohort study aiming to evaluate the detection rate of EGFR gene mutation in patients with advanced NSCLC in a real-word clinical setting, based on liquid biopsy and tissue analyses.


This a multicenter prospective cohort study. This study will be proposed to newly diagnosed advanced NSCLC patients. For included patients, archived paraffin embedded tumor tissue will be used for sequencing ; and blood sample will be collected for research purpose (plasma DNA collection and sequencing).

Both tissue and liquid biopsy samples will follow usual processes and will be sent to the Molecular Pathology laboratory of the Investigation center.

Condition Non Small Cell Lung Cancer, Advanced Solid Tumor
Treatment EGFR gene mutation analysis on liquid biopsy
Clinical Study IdentifierNCT04912687
SponsorInstitut Bergonié
Last Modified on24 March 2022


Yes No Not Sure

Inclusion Criteria

Male or female patients aged ≥ 18 years at time of proposal study
Histologically confirmed non-small cell lung carcinoma
No previous treatment for NSCLC
Indication to EGFR status determination following HAS recommendation
Voluntary signed and dated written informed consent prior to any study specific procedure
Patients with a social security in compliance with the French Law

Exclusion Criteria

Treatment for advanced NSCLC started before liquid biopsy sampling
Involvement in the planning and/or conduct of the study (applies to both Investigator staff and/or staff at the study site)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note